<DOC>
	<DOCNO>NCT02802345</DOCNO>
	<brief_summary>To assess efficacy safety concomitant treatment nintedanib sildenafil Idiopathic Pulmonary Fibrosis ( IPF ) patient advance lung function impairment .</brief_summary>
	<brief_title>Efficacy Safety Nintedanib When Co-administered With Sildenafil Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Inclusion criterion : Written inform consent consistent International Conference HarmonizationGood Clinical Practice local law , sign prior study procedure perform ( include require washout ) ; Male female patient age &gt; = 40 year visit 1 ; A clinical diagnosis IPF within last 6 year visit 1 , base upon American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American thoracic Association 2011 guideline [ P1107084 ] ; Combination highresolution compute tomography ( HRCT ) pattern , available , surgical lung biopsy pattern consistent diagnosis IPF assess investigator base HRCT scan perform within 18 month visit 1 ; Carbon Monoxide Diffusion Capacity ( correct Hb ) less equal 35 % predict normal visit 1 . Exclusion criterion : Previous enrolment trial ; Alanine Transaminase , Aspartate Transaminase &gt; 1.5 fold upper limit normal ( ULN ) visit 1 ; Total bilirubin &gt; 1.5 fold ULN visit 1 ; Relevant airways obstruction ( i.e . prebronchodilator Forced Expiratory Volume 1 second/Forced Vital Capacity &lt; 0.7 visit 1 ) History myocardial infarction within 6 month visit 1 unstable angina within 1 month visit 1 Bleeding Risk : Known genetic predisposition bleeding ; Patients require fibrinolysis , fulldose therapeutic anticoagulation ( e.g . vitamin K antagonist , direct thrombin inhibitor , heparin , hirudin , etc . ) high dose antiplatelet therapy ; History haemorrhagic central nervous system ( CNS ) event within 12 month prior visit 1 ; History haemoptysis haematuria , active gastrointestinal bleeding ulcer and/or major injury surgery within 3 month prior visit 1 ; International normalise ratio ( INR ) &gt; 2 visit 1 ; Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) &gt; 150 % institutional ULN visit 1 ; Planned major surgery trial participation , include lung transplantation , major abdominal major intestinal surgery ; History thrombotic event ( include stroke transient ischemic attack ) within 12 month visit 1 ; Creatinine clearance &lt; 30 mL/min calculate CockcroftGault formula visit 1 ; Presence aortic stenosis ( AS ) per investigator judgement visit 1 ; Severe chronic heart failure : define leave ventricular ejection fraction ( EF ) &lt; 25 % per investigator judgement visit 1 ; Presence idiopathic hypertrophic subaortic stenosis ( IHSS ) per investigator judgement visit 1 ; Seconddegree thirddegree atrioventricular ( AV ) block electrocardiogram ( ECG ) per investigator judgement visit 1 ; Hypotension ( systolic blood pressure [ SBP ] &lt; 100 mm Hg diastolic blood pressure [ DBP ] &lt; 50 mm Hg ) ( symptomatic orthostatic hypotension ) visit 1 ; Uncontrolled systemic hypertension ( SBP &gt; 180 mmHg ; DBP &gt; 100 mmHg ) visit 1 ; Known penile deformity condition ( e.g. , sickle cell anemia , multiple myeloma , leukemia ) may predispose priapism ; Retinitis pigmentosa ; History vision loss ; History nonarteritic ischemic optic neuropathy ; Venoocclusive disease ; History acute IPF exacerbation respiratory infection within 8 week visit 2 . Treatment nitrate , nacetylcysteine , pirfenidone , azathioprine , cyclophosphamide , cyclosporine , prednisone &gt; 15 mg daily &gt; 30 mg every 2 day OR equivalent dose oral corticosteroid well investigational drug within 4 week visit 2 ; Treatment prostaglandin ( e.g. , epoprostenol , treprostinil ) , endothelin1 antagonist ( e.g. , bosentan , sitaxsentan , ambrisentan ) , phosphodiesterase inhibitor ( e.g. , sildenafil , tadalafil , vardenafil ) stimulator guanylatcyclase ( e.g. , riociguat ) within 4 week visit 2 ; Treatment potent cytochrome CYP3A4 inhibitor ketoconazole , itraconazole ritonavir within 4 week visit 2 ; Supplementation Larginine concurrent use grapefruit juice St John 's wort within 4 week visit 2 ; Treatment reduce dose nintedanib ( 100 mg bid ) within 4 week visit 2 ; 27 . Permanent discontinuation nintedanib past due adverse event consider drugrelated ; Known hypersensitivity intolerance nintedanib , sildenafil , galactose , peanut soya component study medication ; A disease condition opinion investigator may interfere test procedure put patient risk participate trial ; Alcohol drug abuse opinion treat physician would interfere treatment ; Further exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>